Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: A descriptive study of a large outpatient oncology practice database, 2000-2007

Clinical Therapeutics

Volumn 31, Issue PART. 2, 2009, Pages 2416-2432

  Wu, Ying ^a   Aravind, Suresh ^a   Ranganathan, Gayatri ^b   Martin, Amber ^b   Nalysnyk, Luba ^b  

^a Johnson and Johnson Pharmaceutical Services   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

anemia; cancer; chemotherapy; dose delay; thrombocytopenia

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; GEMCITABINE; HEMOGLOBIN; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; COMMUNITY CARE; CONTROLLED STUDY; DATA BASE; DESCRIPTIVE RESEARCH; FEMALE; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MULTIPLE CYCLE TREATMENT; OUTPATIENT CARE; OVARY CANCER; SOLID TUMOR; THERAPY DELAY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

AGED; ANEMIA; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; ELECTRONIC HEALTH RECORDS; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATINICS; HUMANS; MALE; NEOPLASMS; OUTPATIENTS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 74549218075     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.020     Document Type: Article

References (22)

1. Capo G., and Waltzman R. Managing hematologic toxicities [published correction appears in J Support Oncol. 2004;2:297]. J Support Oncol 2 (2004) 65-79
2. Buckner C.D., and Maxon J. Chemotherapy-induced anemia: An update from ONS (2004). http://professional.cancer-consultants.com/conference_ons_2004.asp Accessed June 12, 2008
3. In: de Benoist B., McLean E., Egli I., and Cogswell M. (Eds). Worldwide Prevalence of Anaemia 1993-2005. WHO Global Database on Anaemia (2008), World Health Organization, Geneva, Switzerland
4. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: Incidence and treatment [published correction appears in J Natl Cancer Inst. 2000;92:497]. J Natl Cancer Inst 91 (1999) 1616-1634
5. Cella D., Kallich J., McDermott A., and Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Ann Oncol 15 (2004) 979-986
6. Lind M., Vernon C., Cruickshank D., et al. The level of he-moglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 86 (2002) 1243-1249
7. Curt G.A., Breitbart W., Cella D., et al. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist 5 (2000) 353-360
8. Kantarjian H., Giles F., List A., et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 109 (2007) 1705-1714
9. Goldberg G.L., Gibbon D.G., Smith H.O., et al. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. J Clin Oncol 12 (1994) 2317-2320
10. Liou S.Y., Stephens J.M., Carpiuc K.T., et al. Economic burden of haematological adverse effects in cancer patients: A systematic review. Clin Drug Invest 27 (2007) 381-396
11. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf Accessed February 6, 2008
12. Schütte J., Mouridsen H.T., Stewart W., et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Eur J Cancer Clin Oncol 26 (1990) 558-561
13. Motzer R.J., Geller N.L., and Bosl G.J. The effect of a 7-delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients. Cancer 66 (1990) 857-861
14. Ludwig H., Van Belle S., Barrett-Lee P., et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40 (2004) 2293-2306
15. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Cancer and treatment-related anemia. Version 1 (2008). http://www.nccn.org Accessed July 30, 2009
16. Bokemeyer C., Aapro M.S., Courdi A., et al., European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 Update. Eur J Cancer 43 (2007) 258-270
17. Rizzo J.D., Lichtin A.E., Woolf S.H., et al., American Society of Clinical Oncology and American Society of Hematology. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20 (2002) 4083-4107
18. Rizzo J.D., Somerfield M.R., Hagerty K.L., et al. American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood 111 (2008) 25-41
19. Elting L.S., Rubenstein E.B., Martin C.G., et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapythrombocytopenia. J Clin Oncol 19 (2001) 1137-1146
20. Lyman G.H., Dale D.C., and Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 21 (2003) 4524-4531
21. Lyman G.H., Dale D.C., Friedberg J., et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide survey. J Clin Oncol 22 (2004) 4302-4311
22. Calhoun E.A., Chang C.H., Welshman E.E., and Cella D. The impact of chemotherapy delays on quality of life in patients with cancer. Proc Am Soc Clin Oncol 22 (2003) 2220 Abstract